AB 16
Alternative Names: AB-16Latest Information Update: 29 Aug 2024
At a glance
- Originator AUTOTAC Bio
- Class Antiparkinsonians
- Mechanism of Action Alpha-synuclein degraders; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 02 Aug 2024 Early research in Parkinson's disease in South Korea (unspecified route) (AUTOTAC Bio pipeline, August 2024)
- 02 Aug 2024 AUTOTAC Bio plans phase I trial for Alzheimer’s disease between 2024 to 2025 (Unspecified) (AUTOTAC Bio pipeline, August 2024)
- 14 May 2024 AUTOTAC Bio has patent protection for novel P62 ligand compound and composition in USA